Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

"The effect of Six months Adalimumab Treatment on Sick Leaves and retirement in Patients with rheumatoid Arthritis who are at risk of losing their ability to work".

Next Previous
Trial Profile

"The effect of Six months Adalimumab Treatment on Sick Leaves and retirement in Patients with rheumatoid Arthritis who are at risk of losing their ability to work".

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 12 Oct 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Adalimumab (Primary) ; Disease-modifying antirheumatics
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms REWARD

Most Recent Events

  • 12 Oct 2022 Status changed from recruiting to completed.
  • 28 Jul 2011 Additional lead trial centers ans investigators identified as reported by ClinicalTrials.gov.
  • 28 Jul 2011 Planned end date changed from 13 Aug 2010 to 1 Mar 2011 as reported by ClinicalTrials.gov..

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top